Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Michael Rothenberg

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
JCO Precision Oncology|May 26, 2021
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With <i>RET</i> Fusion-Positive Breast CancerSatomi Watanabe, Masayuki Takeda, Tomoyuki Otani, et al.
JCO Precision Oncology|September 6, 2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal MetastasesRobin Guo, Mark Schreyer, Jason C Chang, et al.
Thyroid : Official Journal of the American Thyroid Association|April 16, 2020
Response to RET-Specific Therapy in <i>RET</i> Fusion-Positive Anaplastic Thyroid CarcinomaDora Dias-Santagata, Jochen K Lennerz, Peter M Sadow, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
JCO Precision Oncology|September 14, 2020
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring <i>RET</i> Gene AlterationsMichael V Ortiz, Ulrike Gerdemann, Sandya Govinda Raju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyMelissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastasesRichard J Lee, Philip J Saylor, M Dror Michaelson, et al.
Clinical Lung Cancer|July 15, 2020
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung CarcinoidElizabeth M Kander, Manisha H Shah, Ye Zhou, et al.
Thyroid : Official Journal of the American Thyroid Association|October 26, 2019
A Novel <i>ALK</i> Fusion in Pediatric Medullary Thyroid CarcinomaKirsty Hillier, Amy Hughes, Robert C Shamberger, et al.
JCO Precision Oncology|September 14, 2020
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered CancerLori J Wirth, Takashi Kohno, Hibiki Udagawa, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
JCO Precision Oncology|May 26, 2021
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With <i>RET</i> Fusion-Positive Breast CancerSatomi Watanabe, Masayuki Takeda, Tomoyuki Otani, et al.
JCO Precision Oncology|September 6, 2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal MetastasesRobin Guo, Mark Schreyer, Jason C Chang, et al.
Thyroid : Official Journal of the American Thyroid Association|April 16, 2020
Response to RET-Specific Therapy in <i>RET</i> Fusion-Positive Anaplastic Thyroid CarcinomaDora Dias-Santagata, Jochen K Lennerz, Peter M Sadow, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
JCO Precision Oncology|September 14, 2020
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring <i>RET</i> Gene AlterationsMichael V Ortiz, Ulrike Gerdemann, Sandya Govinda Raju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyMelissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastasesRichard J Lee, Philip J Saylor, M Dror Michaelson, et al.
Clinical Lung Cancer|July 15, 2020
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung CarcinoidElizabeth M Kander, Manisha H Shah, Ye Zhou, et al.
Thyroid : Official Journal of the American Thyroid Association|October 26, 2019
A Novel <i>ALK</i> Fusion in Pediatric Medullary Thyroid CarcinomaKirsty Hillier, Amy Hughes, Robert C Shamberger, et al.
JCO Precision Oncology|September 14, 2020
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered CancerLori J Wirth, Takashi Kohno, Hibiki Udagawa, et al.
Pageof 4